Alantra’s Post

We're delighted to announce that SAI PARENTERALS LIMITED has successfully raised Rs 45 crores in its pre-IPO funding round, facilitated by Spark Capital PWM's Midas Investment Banking team.   What makes this special: - Record timeline: Deal closed in under 30 days - Strong investor confidence from marquee investors including Dr. Bhaskar Rao Bollineni, Gruhas Proptech, SmartGo Prop LLP, and Agilis Partners LLP - Strategic capital to fuel growth ahead of the company's planned IPO   Founded in 2001, Sai Parenterals has established itself as a leading pharmaceutical manufacturer specializing in sterile injectables, oral liquids, and solid formulations across critical therapeutic segments.   This transaction reflects the strength of quality businesses in India's pharmaceutical sector and our commitment to connecting visionary companies with the right partners at the right time.   Congratulations to Anil kumar karusala and the entire team at Sai Parenterals and all the investors on this milestone!   #DealAnnouncement #PreIPO #PharmaSector #InvestmentBanking #SparkCapitalPWM #MidasIB #PrivateEquity #IndianPharma #CapitalRaise RamaRao Yechuri Arpita Vinay Ganashyam S Vaibhav Arren Divya Hari Karthik

Before launching your pharma business, exploring a PCD Company List can give you a strong start. It helps entrepreneurs find reliable partners, compare franchise terms, and choose the right products. With insights from Franchise Medicine Company List, Franchise Pharma Company List, and PCD Pharma Franchise List, you can make smarter investments and grow successfully in the pharma industry. https://lnkd.in/d3xd8dms

PAI Partners eyes $1.2bn sale of French pharma group Ethypharm. The auction is being run with Jefferies Financial Group, and interest has already come from both private equity firms and strategic buyers. PAI bought Ethypharm from Astorg in 2016. The potential exit comes as private equity firms step up healthcare disposals to return capital to investors. Earlier this month, Bain Capital and Cinven sold STADA Group to CapVest Partners for €10bn in Europe’s largest leveraged buyout of 2025, while Advent International divested Zentiva to GTCR LLC for $4.8bn. Discover what makes Ethypharm a $1.2bn target for both strategics and financial sponsors: https://lnkd.in/d3833hzJ #PEInsights #privateequity #sale #pharma

NATCO Pharma has announced its intention to acquire a 35.75 percent equity stake in South Africa’s Adcock Ingram Holdings, in a deal valued at approximately INR 2,000 crore. This transaction is expected to make NATCO Pharma the second-largest shareholder, while Bidvest will retain a 64.25 percent holding. Read more: https://lnkd.in/dCwbj6tF #NatcoPharma #Announcement #AdcockIngram #Bidvest #GlobalHealthCare #PharmaInnovation #PharmaIndustrialndia

**FREE** articles from News & Insights Who should read this? Commercial, strategic, forecasting, BD&L, A&PS, and competitor intelligence professionals in biosimilars companies. What is it? An interview with Accord US president Chrys Kokino about Accord Biopharma's rapidly-rising biosimilars business in the US. Why is it important? In a little over a year, Accord Biopharma has received approval for and launched two major US biosimilars, and has acquired a third from Coherus in the form of the Udenyca franchise. Kokino talks about how offering a wider range of biosimilars has strengthened the firm's overall position, and how the ultimate goal is to become the US market leader - by building on its existing portfolio with a substantial future pipeline and plans to acquire further products. https://lnkd.in/e82SX5kv #Citeline

Theratechnologies Inc. shareholders have overwhelmingly approved a plan of arrangement for acquisition by CB Biotechnology, an affiliate of Future Pak, signaling a notable shift in specialty pharma ownership. The move illustrates a strategic trend: contract manufacturers and distributors stepping into branded specialty portfolios to capture supply chain efficiencies, channel control, and operational leverage. For Commercial and Medical teams, the focus will be on maintaining continuity of patient support, adherence programs, and specialty distribution, while leveraging potential synergies in logistics, packaging, and real-world evidence to strengthen payer relationships. This deal highlights how operational excellence and integrated channel control can become differentiators in a capital-constrained specialty pharma market. Will vertically integrated operators like Future Pak reshape specialty pharma by combining operational efficiency with clinical credibility, or is this a one-off convergence play? 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/dWCqEyCM #SpecialtyPharma #MergersAndAcquisitions #PharmaStrategy #PatientSupport #OperationalExcellence Paul Levesque Tony Di Vincenzo

🌏 Firebrick Pharma Limited (ASX:FRE) strengthens its partnership with the Philippines’ Pharma Nutria N.A., Inc., securing a further AU$102,000 investment at a 31% premium to market! 💰 The funding restores PNAI’s holding above 5% and reinforces confidence in Nasodine® Nasal Spray, ahead of expected Philippines approval in 2026. Dr Peter Molloy says this continued backing highlights long-term belief in Firebrick’s vision and innovation. 🚀 https://lnkd.in/dRsf7Yw5 #ASX #Pharma #Healthcare #Innovation #kapitalesresearch

Boehringer Ingelheim is to move its head offices from Bracknell to Frasers Property Limited’s Winnersh Triangle. The pharmaceutical giant has taken the third and part of the fourth floors at 1180 Winnersh Triangle, a total of 36,479 sq ft, on a 10-year lease. Boehringer Ingelheim will move in Q2 2026 from its current home in Ellesfield Avenue, Bracknell, its head office for more than 50 years. Cushman & Wakefield, which acted for Boehringer Ingelheim on the deal, has been appointed to act on the sale of its current site for redevelopment. https://bit.ly/42pZ8Ld

Dr Reddys Lab 1️⃣1️⃣ EUROPE BUSINESS Dr Reddys Lab delivered strong growth in Europe business,driven by acquired NRT business. Key Growth Drivers in Europe FY2025 1)Revenue from Europe reached 1275₹ Crores Q4 FY25 2) The NRT Portfolio acquired and integrated in the UK , the Europe business grew 29-30% . 3) New launches including biosimilars & complex generics ,added to momentum In FY25 DRL 39 new products across EUROPE Management Commentary a) Europe is positioned as a major growth engine , with strategic priority placed on pipeline execution , further integration of the NRT acquisition. b) Management guided for continued double digit revenue growth in europe for FY26 supported by both organic product launches & monetiziof recent & ongoing acquisition. Summary FY 2025 saw EUROPE emerge as a key growth driver for DRL anchored by the NRT acquisition, above market performance in generics & momentum in biosimilars & speciality products . #equity #drreddyslab🫶🏻 #valuation #finance #pharma #parthvarma

Exciting step forward for us at LTR Pharma — we’ve secured a 33% stake in LevOmega Pty Ltd. By combining biotechnology, nutraceutical and pharmaceutical expertise, LevOmega will develop nature-identical, pharmaceutical-grade omega-3 oil — giving us exposure to the multi-billion-dollar omega-3 market while staying true to our focus on first-in-class therapies for areas of real unmet need. A great example of how we’re building value beyond the lab, positioning ourselves in large, global markets.